We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Immunochromatographic Test Detects Fecal Parasites

By LabMedica International staff writers
Posted on 15 Feb 2012
A recently developed test that detects three pathogenic protozoal parasites in human stool samples has been evaluated. More...


An immunochromatographic (IC) dip strip test simultaneously detects Cryptosporidium spp, Giardia duodenalis, and Entamoeba histolytica that are known to cause diarrheal disease.

At the University of Zaragoza (Spain) scientists collected 160 stool samples from patients with intestinal discomfort or diarrhea, in which parasitic infections needed to be ruled out. Samples were taken and analyzed by microscopic examination and by different IC tests, from July 2008 to December 2008. Fresh specimens were processed within 24 hours of collection. Besides the IC tests, both enzyme-linked immunosorbent assays (ELISA) and heminested polymerase chain reactions (PCR) were performed. Microscopy and PCR were the “gold standard” reference techniques and the results of the RidaQuick IC triple stool test were compared with those obtained with ELISA and IC single test for the three parasites.

Microscopic examination revealed that 22 samples were diagnosed as positive for Cryptosporidium spp., 31 for Giardia duodenalis, 41 for Entamoeba histolytica/dispar, and 68 had a negative diagnosis for the three parasites. Results of RidaQuick IC tests (R-Biopharm; Darmstadt, Germany) show sensitivities of 70%-72% for Cryptosporidium, 90%-97% for Giardia and 62.5% for Entamoeba histolytica. Specificities for these three protozoa were 93.6%-94.9%, greater than 99% and 96.1%, respectively. In all diagnoses, agreement with microscopy and PCR was over 90%, except in the triple test and microscopy in E. histolytica detection that was 76.3%, due to the inability of microscopy to differentiate E. histolytica from nonpathogenic species such as E. dispar or E. moshkovskii.

The authors concluded that the triple stool immunoassays provide adequate sensitivities and specificities with clinically relevant cost-effectiveness. They can be used in outbreak situations, for screening proposals and for massive assays in endemic areas where a large number of samples must be analyzed or as complementary test for individual diagnosis since the entire test could be performed in 15–20 minutes. The study was published online on January 20, 2012, in the Journal of Clinical Microbiology & Infectious Diseases.

Related Links:

University of Zaragoza
R-Biopharm



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Analyzer
respons® UDS100
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.